Natarajan Muthusamy Selected Research

Lymphoma (Lymphomas)

9/2023	A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models.
10/2012	A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders.
4/2012	Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.
3/2009	The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia.
12/2008	Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.
4/2008	Liposomal coencapsulated fludarabine and mitoxantrone for lymphoproliferative disorder treatment.
1/2008	A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
1/2008	FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.
10/2007	Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Natarajan Muthusamy Research Topics

Disease

52	Neoplasms (Cancer) 10/2023 - 12/2002
36	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 11/2022 - 10/2007
17	Leukemia 10/2023 - 08/2006
9	Lymphoma (Lymphomas) 09/2023 - 10/2007
9	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 06/2023 - 06/2009
8	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 10/2023 - 06/2010
6	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 09/2007
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 09/2023 - 04/2008
4	B-Cell Lymphoma (Lymphoma, B Cell) 01/2021 - 01/2008
4	Breast Neoplasms (Breast Cancer) 01/2020 - 01/2016
3	Hematologic Neoplasms (Hematological Malignancy) 01/2018 - 01/2013
3	Bronchiolitis Obliterans Syndrome 01/2016 - 11/2014
2	Melanoma (Melanoma, Malignant) 01/2020 - 01/2016
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2018 - 09/2017
2	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 10/2012 - 04/2008
2	Multiple Sclerosis 12/2011 - 09/2007
2	Hepatocellular Carcinoma (Hepatoma) 06/2011 - 02/2008
1	Cytokine Release Syndrome 10/2023
1	Colitis 01/2019
1	Rectal Prolapse 01/2019
1	Disease Progression 01/2019
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2018
1	Glioblastoma (Glioblastoma Multiforme) 01/2018
1	T-Cell Leukemia (Leukemia, T Cell) 01/2018
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2018

Drug/Important Bio-Agent (IBA)

12	Proteins (Proteins, Gene)FDA Link 06/2023 - 10/2002
9	ibrutinibIBA 09/2023 - 10/2013
9	Fingolimod Hydrochloride (FTY720)FDA Link 09/2015 - 09/2007
7	Monoclonal AntibodiesIBA 09/2023 - 03/2009
6	AntibodiesIBA 10/2022 - 10/2007
6	Lenalidomide (CC 5013)FDA Link 01/2016 - 10/2008
6	Rituximab (Mabthera)FDA Link 03/2013 - 05/2008
5	CytokinesIBA 10/2023 - 02/2011
5	milatuzumabIBA 09/2023 - 04/2011
5	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 10/2013
5	OSU-2SIBA 01/2022 - 06/2011
5	interleukin-21 (interleukin 21)IBA 01/2020 - 05/2008
4	RNA (Ribonucleic Acid)IBA 10/2020 - 06/2009
4	OligonucleotidesIBA 01/2013 - 06/2009
3	AntigensIBA 10/2023 - 02/2010
3	mouse MIRN29 microRNAIBA 01/2019 - 06/2009
3	MicroRNAs (MicroRNA)IBA 06/2012 - 06/2009
3	fludarabineIBA 05/2008 - 08/2006
2	Bispecific AntibodiesIBA 10/2023 - 04/2012
2	Chimeric Antigen ReceptorsIBA 09/2023 - 03/2016
2	Phosphotransferases (Kinase)IBA 02/2018 - 09/2007
2	Interleukin-10 (Interleukin 10)IBA 01/2018 - 12/2015
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2016 - 01/2016
2	emt protein-tyrosine kinase (IL2-inducible T-cell kinase)IBA 01/2016 - 11/2014
2	Interleukin-21 ReceptorsIBA 01/2016 - 06/2015
2	OligodeoxyribonucleotidesIBA 06/2015 - 02/2010
2	Cytarabine (Cytosar-U)FDA LinkGeneric 06/2015 - 02/2010
2	Antisense OligonucleotidesIBA 06/2015 - 01/2009
2	TetraspaninsIBA 01/2015 - 09/2013
2	Interleukin-2 (IL2)IBA 11/2014 - 01/2010
2	Transferrin (beta 2 Transferrin)IBA 05/2013 - 02/2010
2	Liposomes (Liposome)IBA 01/2013 - 04/2008
2	Immunoglobulin G (IgG)IBA 04/2012 - 03/2009
2	Cyclin D1IBA 12/2011 - 06/2010
2	Immunosuppressive Agents (Immunosuppressants)IBA 06/2011 - 02/2008
2	Reactive Oxygen Species (Oxygen Radicals)IBA 04/2011 - 07/2010
2	Therapeutic UsesIBA 02/2010 - 06/2009
2	Messenger RNA (mRNA)IBA 01/2010 - 01/2009
2	DNA (Deoxyribonucleic Acid)IBA 06/2009 - 12/2002
1	blinatumomabIBA 10/2023
1	erdafitinibIBA 10/2023
1	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 10/2023
1	Cyclin-Dependent Kinase 9IBA 06/2023
1	Proteolysis Targeting ChimeraIBA 06/2023
1	CTLA-4 AntigenIBA 01/2022
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2022
1	Protein Phosphatase 2 (Protein Phosphatase 2A)IBA 01/2022
1	Receptor Tyrosine Kinase-like Orphan ReceptorsIBA 01/2021
1	Immunoconjugates (Immunoconjugate)IBA 01/2021
1	venetoclaxIBA 01/2021
1	EnzymesIBA 01/2020
1	BI-1347IBA 01/2020
1	idelalisibIBA 01/2019
1	BI 836858IBA 02/2018
1	BI 6727IBA 02/2018
1	Diphtheria ToxinIBA 01/2018
1	Interleukin-3 Receptors (Interleukin 3 Receptor)IBA 01/2018
1	tagraxofuspIBA 01/2018
1	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 01/2018
1	Fc Receptors (Fc Receptor)IBA 01/2018
1	Interleukin-3 (Interleukin 3)IBA 01/2018
1	Mitogen-Activated Protein KinasesIBA 11/2017
1	withaferin AIBA 09/2017
1	acalabrutinibIBA 08/2017
1	NK Cell Lectin-Like Receptor Subfamily CIBA 01/2016
1	monalizumabIBA 01/2016
1	Ribonucleotide Reductases (Ribonucleotide Reductase)IBA 06/2015
1	GTI2040IBA 06/2015
1	Lipid NanoparticlesIBA 06/2015

Therapy/Procedure

32	Therapeutics 11/2022 - 10/2007
7	Immunotherapy 10/2023 - 04/2010
4	Drug Therapy (Chemotherapy) 01/2021 - 02/2010
1	Euthanasia (Mercy Killing) 01/2019
1	Cell Transplantation 01/2018
1	Hematopoietic Stem Cell Transplantation 11/2014